Advice
following a full submission:
saxagliptin (Onglyza®) is accepted for restricted use within NHS Scotland.
Indication under review: in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
SMC restriction: as an alternative dipeptidyl peptidase-4 inhibitor option.
Treatment with saxagliptin reduces glycosylated haemoglobin, HbA1c, levels significantly more than placebo when used in combination with metformin and a sulphonylurea. Indirect comparisons demonstrated similar efficacy to other dipeptidyl peptidase-4 inhibitors.
Download detailed advice150KB (PDF)
Medicine details
- Medicine name:
- saxagliptin (Onglyza)
- SMC ID:
- 918/13
- Indication:
- In adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 December 2013